Despite the introduction of novel and more targeted immunosuppressive drugs, the long-term survival of kidney transplants has not improved satisfactorily. Early antigen-independent intragraft inflammation plays a critical role in the initiation of the alloimmune response and impacts long-term graft function. Complement activation is a key player both in ischemia/ reperfusion injury (IRI) as well as in adaptive antigraft immune response after kidney transplantation. Since the alternative pathway (AP) amplifies complement activation regardless of the initiation pathways and renal IR injured cells undergo uncontrolled complement activation, we speculated whether selective blockade of AP could be a strategy for prolonging kidney graft survival. Here we showed that Balb/c kidneys transplanted in factor b deficient C57 mice underwent reduced IRI and diminished T cellmediated rejection. In in vitro studies, we found that fb deficiency in T cells and dendritic cells conferred intrinsic impaired alloreactive/allostimulatory functions, respectively, both in direct and indirect pathways of alloantigen presentation. By administering anti-fB antibody to C57 wt recipients in the early post Balb/c kidney transplant phases, we documented that inhibition of AP during both ischemia/ reperfusion and early adaptive immune response is necessary for prolonging graft survival. These findings may have implication for the use of AP inhibitors in clinical kidney transplantation.
Abbreviations: AP, alternative pathway of complement; fB, complement factor B; IFNc, interferon gamma;
IL-1b, interleukin-1b;
Introduction
The identification of novel T cell-targeting immunosuppressive strategies has allowed important progress to be made regarding short-term outcomes in kidney transplantation. However, long-term kidney graft survival has not improved significantly and remains suboptimal (1) . Recently, evidence has accumulated that antigen-independent graft injury, which strongly promotes and sustains the adaptive immune response, critically impacts long-term graft outcome. This suggests that reducing intragraft inflammation may have great potential for improving transplantation outcomes. Emerging evidence has identified complement activation as an essential participant in both the innate and adaptive immune response to an allograft (2, 3) .
Complement activation is initiated through three main pathways: the classical pathway triggered by immune complexes, the lectin pathway triggered by mannose-binding lectins and ficolins, and the alternative pathway (AP), which is activated continuously in plasma by low-degree hydrolysis of C3. Hydrolyzed C3 binds to factor B (fB) and initiates fD-dependent assembly of the AP C3 convertase, which cleaves C3 to C3a and C3b. C3b deposits on cell surfaces and forms the C3 convertase amplification loop (4) . All three pathways converge in the generation of C5 convertases that cleave C5, generating the main effector molecules of the complement system: the membrane-attack complex (MAC, C5b-9) and the anaphylatoxin C5a (2, 4) .
Several experimental models of warm kidney ischemia/ reperfusion (5, 6) and transplantation (7) (8) (9) have shown a clear-cut role for complement in kidney ischemia/ reperfusion injury (IRI), where the main targets are tubular epithelial cells. The high sensitivity of tubular epithelial cells to complement has been attributed to ischemiainduced downregulation of the expression of complement regulators (6) and upregulation of the local production of complement components (8, 9) . The finding that C3-and fBdeficient mice (10) , as well as mice given an anti-fB antibody (5) were protected from kidney reperfusion damage following warm ischemia-whereas C4 deficient mice did not (11, 12) -indicates that AP plays a crucial role in renal IRI.
Recent studies have definitely indicated that complement regulates cell immunity also. Macrophages upregulate fB expression in response to inflammatory stimuli (13, 14) . T cells and antigen-presenting cells (APCs), during cognate interaction, both produce complement components and release C3a and C5a (15) (16) (17) , which directly augment the adaptive immune response by binding to their receptors on T cells and APCs (18, 19) . The relevance of complement activation in the adaptive immune response against the graft is supported by findings that graft and/or recipient deficiency of C5aR (20) or inhibition of C5aR by a receptor antagonist (21) modulates T cell-dependent kidney transplant rejection. Local complement activation in the graft also plays a role in T cell alloimmune response, as documented by data that wt mice recipient of a C3-deficient kidney demonstrated defective T cell priming and did not reject the graft (8) . Thus, complement activation appears to contribute to kidney graft rejection at multiple levels: by mediating IRI, increasing graft immunogenicity, and promoting adaptive alloimmune response.
In this picture, AP could have a major role for several reasons: AP acts as an amplification loop even when complement activation has been initiated by classical or lectin pathways (22) ; because of its spontaneous activating capability, AP requires tight regulation, and renal cells injured by IRI lose the capability to control AP activation, setting the stage for the amplification of injury (22) . This evidence indicates AP as a potential therapeutic target in kidney transplantation. In addition, the selective inhibition of AP may offer therapeutic benefits without the potential side-effects associated with unselective complement inhibition at the level of C3, such as infections and autoimmunity (23) .
Therefore, it remains to be established whether preventing amplification of the complement cascade by blocking AP improves kidney graft outcomes.
Here we formally evaluated, in a model of kidney allotransplantation in fb-deficient mice, the impact of complement AP on posttransplant IRI, T cell alloreactivity and graft survival, as well as the impact of fb deficiency in the donor kidney.
We also assessed the effect of posttransplant administration of an anti-fB antibody on kidney allograft outcome.
Materials and Methods
Detailed methods can be found in Data S1.
Results
Factor b-deficient recipient mice had prolonged kidney allograft survival To assess the effect of the lack of a functional AP in recipient mice on kidney allograft survival and function, fb À/À (n = 7) and wt (n = 10) C57 mice received a Balb/c kidney graft pre-exposed to 20 min cold-ischemia ( Figure 1A ). À/À recipients were protected from early graft dysfunction, as shown by significantly lower blood urea nitrogen (BUN) levels 24 h posttransplantation versus wt recipients ( Figure 1C ). BUN levels were significantly lower in fb À/À recipients than in wt recipients also at day 7 posttransplant. Thereafter, kidney graft function deteriorated slightly until >60 days posttransplant. At the later time points, the BUN levels in fb À/À recipients remained lower than in the small fraction of surviving wt recipients that did not reject their grafts, although the difference did not reach statistical significance ( Figure 1C ).
Reduced intragraft complement activation in fb
À/À recipients To evaluate the impact of recipient fb deficiency on intragraft complement production and deposition following IRI, additional fb À/À and wt mice undergoing Balb/c kidney transplants were euthanized 24-48 h (n = 3) or 7 days (n = 3) posttransplantation. At 24-48 h posttransplant, C3 mRNA levels increased eightfold in kidney allografts from both fb-deficient and -sufficient mice ( Figure 2A ). However, both 24-48 h and 7 days posttransplant, in kidney grafts from fb À/À recipients very faint complement C3 deposits could be seen compared with the diffuse and intense C3 staining along the tubular membrane in grafts from wt recipients (Figures 2B-D) . At 7 days posttransplant, complement C9 staining, indicating C5b-9 deposition, was barely detectable in tubuli ( Figure 2E ) and glomeruli ( Figure 2G ) of kidney grafts from fb À/À recipients, whereas strong tubular and glomerular C9 staining was detected in the grafts from wt recipients ( Figures 2F, H) . C9 staining scores in tubuli and glomeruli were 6-10 times lower in allografts from fb À/À recipients than from wt recipients ( Figure 2I ).
These findings indicate that recipient fb deficiency prevented complement deposition and activation in kidney allografts in response to IRI, without altering local C3 mRNA expression.
Recipient fb deficiency protected kidney allografts from IRI and inflammation We next evaluated the impact of fb deficiency on early graft injury and inflammation. Balb/c grafts taken from fb À/À recipients 24-48 h posttransplantation had reduced tubular damage compared to wt recipients which, in contrast, showed marked tubular alterations such as atrophy and casts ( Figures 3A and B) . Neutrophil infiltration is a major component that contributes to the process of reperfusion injury, by releasing oxygen radicals and proteases. We found a significantly lower number of graft-infiltrating neutrophils in fb À/À recipients compared to wt mice ( Figures 3C and D ).
These data demonstrate that kidney allografts transplanted into recipients with defective AP activation undergo less severe IRI, which is possibly related to decreased intragraft neutrophil infiltration.
Following IRI, the ischemic kidney upregulates the expression of chemokines, such as CCL2/MCP-1 (21), in a complement-dependent manner (24) , promoting the subsequent infiltration of macrophages that sustain inflammation. We therefore evaluated mRNA expression of CCL2/MCP-1 in Balb/c allografts from fb À/À or wt recipients both at 24-48 h and at day 7 posttransplant. The expression of CCL2 mRNA increased at 24-48 h posttransplant in Balb/c grafts from both fb À/À and wt recipients, compared to na€ ıve mice ( Figure 3E ). However, CCL2 mRNA expression in Balb/c grafts from fb À/À recipients did not increase further at day 7 posttransplant, whereas it did so in allografts from wt recipients, reaching very high expression levels ( Figure 3E Reduced infiltration of neutrophils and macrophages in kidneys from fb À/À recipients is not attributable to intrinsic migratory defects of fb À/À cells, as documented by a similar number of peritoneal neutrophils and macrophages harvested from casein-injected fb À/À and wt mice ( Figures 3H and I) . Factor b À/À neutrophils expressed CXCR2 ( Figure 3J ), and in response to LPS (Lipopolysaccharide) released myeloperoxidase ( Figure 3K ), TNFa ( Figure 3L ) and interleukin-1b (IL-1b) ( Figure 3M ) at the same levels as wt cells. After LPS stimulation, macrophages isolated from fb À/À mice released similar amount of TNFa ( Figure 3L ), whereas they showed a trend toward less IL-1b release than wt cells ( Figure 3M ).
Reduced adaptive T cell response to kidney allografts in fb À/À mice Kidney graft tissues collected 7 days posttransplantation were analyzed for T cell-mediated acute rejection. At immunohistochemical analysis, allografts from fb À/À recipients had a degree of T cell infiltration that was much lower compared to wt recipients, both at interstitial and perivascular levels ( Figures 4A-D) . Consistently, at day 7 after transplantation, allografts from fb À/À recipients also had significantly reduced mRNA expression of the T cell-chemokines CXCL9 and CXCL10 compared to wt recipients ( Figure 4E ). Notably, the percentage of Foxp3-expressing T cells among graft-infiltrating CD4 + T cells was comparable between fb À/À and wt recipients ( Figure 4F ).
To investigate the effect that the deficiency of functional AP in the recipient has on T cell response, we evaluated T cell phenotype and ex vivo alloreactivity of splenocytes These findings suggest that long-term graft acceptance in fb-deficient mice is characterized by reduced chronic allograft injury, reduced graft CD8 + T cell infiltration, and increased intragraft CD4 + Foxp3 + regulatory T cell localization.
Factor b-deficient T cells and dendritic cells demonstrated impaired alloreactivity and allostimulatory capacity, respectively, in both direct and indirect pathways of antigen presentation To evaluate whether intrinsic fb deficiency in recipient adaptive immune cells resulted directly in an impaired alloimmune response, we evaluated the alloreactivity and allostimulatory capacity of T cells and dendritic cells (DCs) isolated from na€ ıve untransplanted fb À/À and wt mice, in response to Balb/c alloantigens presented either by direct or indirect pathways.
CD4
+ T cells from na€ ıve fb À/À (n = 4) and wt (n = 4) mice were stimulated with LPS-activated Balb/c DCs. Mixed lymphocyte reactions (MLRs) were conducted either in serum-free media to exclude any possible interference from the exogenous fB present in FCS or in complete media. Factor b-deficient CD4 + T cells had a twofold lower frequency of IFNc-producing cells than wt CD4 + T cells ( Figure 6A ), both when MLR was conducted in the presence of FCS or in serum-free condition. When DCs from fb À/À mice were used as stimulators of allogeneic Balb/c CD4 + T cells, they had significantly reduced allostimulatory capacity compared to wt DCs, both in the presence and absence of serum ( Figure 6B ). CD4 + T cells and DCs from fb À/À and wt mice were also assayed in the indirect pathway of antigen presentation setting. DCs were incubated together with the Balb/c allopeptide, the IFNc response was completely eliminated ( Figure 6C ).
These in vitro findings indicate that fb deficiency confers impaired reactivity to alloantigens on CD4 + T cells and reduced capability to present alloantigens and activate T cells both through direct and indirect pathways on DCs.
Donor kidney fb deficiency did not prevent graft complement deposits and did not protect from acute cellular rejection Although fB is a circulating complement component and is mainly synthesized in the liver, the kidney itself can produce fB (2).
To investigate whether local (graft) AP deficiency results in inhibition of complement activation and in better euthanized (days 7-14 posttransplant) and grafts collected for immunohistochemical and mRNA expression analysis. fb À/À kidney grafts showed deposits of complement C3 and C5b-9 in tubuli and glomeruli comparable to those in wt allografts ( Figure 7D ). Similarly, graft mRNA expression of CCL2/MCP-1 and macrophage infiltration ( Figures 7E-H) as well as numbers of CD8 + and CD4 + T cells infiltrating the interstitial and perivascular areas, and graft expression of CXCL9 and CXCL10 mRNA ( Figures 7I-K) were not significantly different between fb À/À and wt rejected allografts. These findings indicate that donor kidney fb deficiency did not protect the graft from complement activation and deposition and did not inhibit acute cellular kidney allograft rejection.
Administration of an anti-fB antibody during the first 2 weeks posttransplant prevented IRI and acute cellular rejection From the clinical perspective of therapeutic inhibition of AP in kidney transplantation, we evaluated the effect of administering a blocking anti-mouse fB mAb on kidney allograft outcome. The capability of the anti-fB mAb to inhibit AP during T cell-APC cognate interaction was confirmed in in vitro MLR in serum-free media, demonstrating significant IFNc-spot inhibition in wt C57
+ T cells in response to Balb/c stimulator cells ( Figure 8A ).
Wild-type C57 mice receiving a Balb/c kidney were given anti-fB mAb according to two schedules: four recipient mice received 7 daily i.p. injections of 3 mg anti-fB mAb from day À1 to day 5 posttransplant (short treatment); an additional 4 recipient mice received 16 daily i.p. injections of 3 mg anti-fB mAb from day À1 to day +14 posttransplant (long treatment). These schedules allowed us to evaluate the impact of inhibiting complementmediated IRI only (short treatment) or of inhibiting both IRI and complement-dependent early anti-graft T cell activation (long treatment) on kidney allograft outcomes. Recipient mice given the short anti-fB mAb treatment rejected the allograft at a rate similar to that of untreated mice (MST: 24 days, Figure 8B ), despite that the treatment effectively prevented early graft dysfunction in response to IRI ( Figure 8C ). In contrast, the long anti-fB mAb treatment resulted in a significant prolongation of kidney allograft survival (MST: 86 days, Figure 8B ) and in the preservation of graft function, as demonstrated by reduced BUN levels at both 1 and 7 days posttransplant ( Figure 8C ). Additional wt C57 mice transplanted with Balb/c kidneys were treated with anti-fB mAb and euthanized at 48 h (n = 3) and 7 days (n = 3) posttransplant. DCs preexposed to LPS were used as stimulators in MLR against responder Balb/c CD4 + T cells (from n = 4 mice), either in serum-free conditions or in the presence of 5% FCS. In both conditions, fb-deficient DCs showed a lower capability to induce IFNc-producing spots in MLR, compared to wt DCs; *p < 0.05 versus B6 DCs wt (B). In the indirect pathway, CD4 + T cells from fb À/À mice showed a lower frequency of IFNc-producing cells when stimulated by wt DCs; conversely fb À/À DCs induced a lower frequency of IFNc-producing clones in wt syngeneic CD4 + T cells in the presence of Balb/c allopeptide QEGPEYWEEQTRAK. When both DCs and CD4 + T cells from fb deficient mice were incubated together, the IFNc spots were undetectable (C). Results are mean AE SEM of IFNc spots in the presence of the peptide after subtraction of IFNc in the absence of peptide (usually less than 3-5 spots), *p < 0.05 versus CD4 + T cells wt + DCs wt. DCs, dendritic cells; FCS, fetal calf serum; IFNc, interferon gamma; LPS, lipopolysaccharide; MLR, mixed lymphocyte reaction. Figure 7 : Graft fb deficiency does not prevent intragraft complement deposition, inflammatory cell infiltration, and chemokine expression and does not prolong kidney allograft survival. Balb/c recipient mice were transplanted with kidneys from either fb deficient (n = 4) or C57 wt (n = 7) donor mice pre-exposed to 20 min cold ischemia time (A). Additional Balb/c recipients (n = 4) transplanted with wt C57 kidneys were given anti-fB mAb from day À1 to day +14 posttransplantation (A). Recipients of fb À/À grafts rejected the transplanted kidney similarly to recipients of wt grafts (B) and graft function, evaluated as BUN levels (C), progressively deteriorated in both groups. At variance, recipients of wt grafts administered with the anti-fB mAb showed a significant prolongation of graft survival with reduced BUN levels at day 7 and 10 posttransplant compared to untreated Balb/c recipients of wt or fb deficient grafts (B,C). Data are mean AE standard error of the mean (SEM), *p < 0.05 versus fb-deficient and wt grafts;°p < 0.05 versus recipients of wt grafts. The scores of tubular complement C3 deposits as well as tubular and glomerular C9 deposits (D) were not significantly different between recipients rejecting fb deficient or wt grafts. CCL-2/MCP-1 mRNA expression (E), the number of infiltrating macrophages (H) as well as the number of CD8 + (I) and CD4 + (J) T cells infiltrating interstitial and perivascular graft zones and T cell chemokine mRNA expression (K) were similar between fb-deficient and C57 wt (n = 4) grafts. Data are mean AE SEM, p = NS. Panels We found a very faint intragraft staining for C3 and C9, despite marked upregulation of C3 mRNA expression ( Figures 8D-F) , and a significantly reduced tubular damage ( Figures 8G and H 
Discussion
Here we show that, in a murine model of kidney allotransplantation, recipient deficiency for fb, a key component of AP, reduced IRI, mitigated acute cellular rejection, and prolonged kidney graft survival. Factor b deficiency conferred an intrinsically reduced Th1 response on CD4 + T cells and an impaired allostimulatory capacity on DCs in both direct and indirect pathways of alloantigen presentation. In contrast, AP deficiency in the graft had no significant impact on kidney allograft survival. Finally, by administering a blocking anti-fB antibody to recipient mice, we demonstrated that inhibition of AP during both ischemia/reperfusion and the early activation of alloimmune T cell response are required to improve kidney graft outcomes.
In experimental models of either kidney warm ischemia or transplantation, complement activation occurred early after IRI and localized mainly at the level of the tubular epithelium (2, (6) (7) (8) . The loss and abnormal cellular polarization of complement inhibitors (6) as well as local generation of complement effector molecules (7-9) have been proposed as mechanisms that trigger complement activation following IRI. Transplant experiments between complement C3-sufficient and -deficient mice showed that locally synthesized C3 produced by and deposited on graft tubular cells was essential for complementmediated IRI in both syngeneic (9) and allogeneic kidney (8) transplantation, whereas recipient circulating C3 had a negligible effect. Our finding that C3 expression increased eightfold after transplantation in kidney allografts confirmed the upregulation of kidney complement effector molecules in posttransplant IRI. However, we provide evidence that recipient fB is not dispensable for local complement activation in the graft, since C3 and C9 staining was almost fully prevented in kidneys transplanted into fb-deficient mice or in wt recipient mice given anti-fB antibody. These findings are consistent with previous data showing that fb-deficient mice (10) or mice given an anti-fB antibody (5) and undergoing warm kidney IRI had no evidence of C3 or C5b-9 deposition in the kidney.
Altogether, the published and present data suggest that complement activation in renal IRI depends critically on both graft C3 upregulation and on an intact AP in the recipient. Our present findings that grafts with fb deficiency (but C3 sufficiency) showed complement deposition and inflammation comparable to that of wt mice support this hypothesis.
It is also relevant that preventing AP activation resulted in reduced early tubular injury and neutrophil influx in the kidney allografts, extending previous data in the mouse model of warm IRI to the kidney transplant setting (5, 10) . Lower IRI in the kidney grafts of fb À/À recipients was paralleled by reduced expression of the CCL2/MCP1 chemokine and by reduced macrophage influx. Upregulation of chemokine expression has been suggested as one of the main pathways through which the terminal complement effectors C5a and C5b-9 contribute to IRI inflammation after renal pedicle clamping (11, 26, 27) or allotransplantation (21, 28) .
We also demonstrated that preventing AP activation was associated with reduced graft expression of the T cell Figure 8 : Administration of a blocking anti-fB antibody prolonged kidney graft survival. The addition of anti-fB mAb, at doses of 0.5, 1, and 1.5 lg/mL significantly reduced the frequency of IFNc-producing cells in in vitro MLR with splenocytes from C57 na€ ıve mice as responders and Balb/c splenocytes as stimulators (A, one representative of three independent experiments). (B) Administration of the anti-fB mAb (3 mg, daily i.p. injection) to C57 wt recipients from the day before to 14 days posttransplant (n = 4) significantly prolonged Balb/c kidney allograft survival compared to mice given the anti-fB mAb from the day before until day +5 posttransplant (n = 4). Graft survival was compared to that from untreated mice (n = 10, of note, treatment of additional two recipient mice with an isotype IgG1 antibody resulted in similar graft survival-15 and 30 days-and function to those of untreated mice). (C) Mice given both anti-fB mAb treatment schedules had lower BUN levels than untreated recipient mice 1 day posttransplant. AntifB mAb administration from the day before until 14 days posttransplant was associated with better graft function at day 7 posttransplant compared with untreated mice or mice given the short Ab treatment. Results are mean AE standard error of the mean (SEM); *p < 0.05 versus untreated;°p < 0.05 versus short anti-fB Ab treatment. chemokines CXCL9 and CXCL10, and with diminished numbers of graft-infiltrating CD4 + and CD8 + T cells. This finding confirms a previous study in a heart transplant model showing that inhibiting the terminal pathway of complement with an anti-C5 antibody limited complementinduced upregulation of CXCL9 and CXCL10 in the donor organ and inhibited T cell trafficking into the graft (29) .
Notably, reduced intragraft T cell infiltration in fb-deficient mice was associated with impaired anti-donor T cell priming. This confirmed previous studies in experimental models of kidney transplantation showing that the degree of complement activation after transplantation has a remarkable impact on donor-specific T cell activation (8, 20) .
Based on these findings, we can hypothesize that preventing complement-mediated IRI and graft inflammation lessened the immunogenicity of the graft and inhibited donor APC maturation and migration into recipient lymphoid organs and the consequent T cell priming and trafficking into the donor organ.
Both innate and adaptive immune cells produce fB (4) . Macrophages upregulate fB synthesis in response to proinflammatory cytokines (13) or Toll-like receptor activation (14) . APC and T cells produce complement components during their interaction (15) (16) (17) , including fB (15) (16) (17) , and evidence is available that AP has a role in enhancing the adaptive immune response (18, 19, 30, 31) . Therefore, we speculated whether in our model the capacity of fb-deficient immune cells to respond to inflammatory stimuli and to react against alloantigens was impaired. Through in vitro studies, we found that fb-deficient neutrophils and macrophages have unaltered migratory activity and effector functions, whereas APCs had a reduced capability to induce Th1 response, both through direct and indirect alloantigen presentation. Furthermore, fb-deficient T cells had an impaired capability to differentiate into Th1 cells when stimulated by wt allogeneic DCs via the direct alloantigen presentation pathway. Remarkably, deleting fb both in CD4 + T cells and DC resulted in complete impairment of the Th1 response during indirect antigen presentation.
These observations suggest that, in our model, fb deficiency in recipient immune cells contributes to prolonging graft survival by conferring on T cells a reduced capability to be activated by alloantigens, both in the early phase of direct antigen presentation by graft APCs and in the later phase, when the indirect pathway, mediated by recipient fb deficient DCs, takes place.
Altogether, the data presented here suggest that inhibition of the AP could be a therapeutic option for mitigating IRI, which has profound effects on the organ's recovery and the development of long-term damage, and on restraining
